Navigation Links
Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia

HAMPTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).  The trial, which commenced in December 2009, enrolled its last patient six weeks ahead of schedule. The trial design includes a one-year follow-up assessment, as discussed with the U.S. Food and Drug Administration (FDA).

Bronchopulmonary dysplasia is a cause of chronic lung disease that develops most commonly in pre-term infants (less than 30 weeks of gestational age) with birth weights less than 1,250 grams who are treated with oxygen and positive-pressure ventilation. Bronchopulmonary dysplasia is even more pronounced in very pre-term infants (less than 26 weeks of gestational age) with birth weights less than 1,000 grams and who have been treated for respiratory distress syndrome.

This multi-center, double blind, placebo-controlled, randomized clinical trial, entitled, Inhaled Nitric Oxide for the Prevention of Bronchopulmonary Dysplasia in Preterm Infants, or the "NewNO Trial," aims to determine whether preterm infants who require mechanical ventilation or positive pressure support at any point during days 5 to 14 after birth may benefit from treatment with iNO. In eligible subjects, iNO was administered continuously at a starting dose of 20ppm for a duration of 24 days.

"The treatment of BPD is an area of great interest and much debate within the neonatology community given the challenges in treating this condition," stated Daniel Tasse, Chairman and CEO of Ikaria.  "We are hopeful that the data from this trial will provide the definitive answers the medical community has been seeking, particularly in light of the recommendations generated by the 2010 NIH Consensus Conference on BPD."

"Enthusiastic enrollment, which allowed us to beat the original enrollment timeline, speaks both to the unmet medical need and the profound interest by the medical community to address BPD," added Douglas A. Greene, M.D., Executive Vice President of Research & Development at Ikaria.

Inhaled nitric oxide selectively relaxes the cells of the pulmonary vasculature, resulting in increased blood flow through the lungs and delivery of more oxygenated blood to the body. Inhaled nitric oxide may also have beneficial effects on the development of pulmonary blood vessels and airspaces.  

Inhaled nitric oxide is available as INOMAX® (nitric oxide) for inhalation, a vasodilator, which, in conjunction with ventilation and other appropriate agents, treats term and near-term newborns (>34 weeks gestation) with hypoxic respiratory failure associated with evidence of pulmonary hypertension.  INOMAX is not approved for use in BPD.

INOMAX® is a vasodilator, which, in conjunction with ventilator support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOMAX may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy.  Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, and therefore may cause airway inflammation and damage. Methemoglobin, NO2, and FiO2 should be monitored during nitric oxide administration. 

Please see attached prescribing information.  For additional information about INOMAX, please visit

About Ikaria, Inc.
Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is investigating additional indications for INOMAX in bronchopulmonary dysplasia, and for inhaled nitric oxide with the INOpulse® DS drug-delivery system as a drug-device combination product in pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Ikaria's late-stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for Hepatorenal Syndrome Type 1; as well as Bioabsorbable Cardiac Matrix (BCM), a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with a research facility in Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit Contact:Media Contact:Samina Bari

Claire SojdaIkaria, Inc.

Tiberend Strategic Advisors, Inc.(908) 238-6372  




SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
2. Ikaria® to Present at 2011 BIO Investor Forum
3. Ikaria® To Present at 2011 BIO Business Forum and International Convention
4. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
5. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
6. Auxogyn Completes $20 Million In Series A Funding
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. MiMedx Group Completes $5,000,000 Private Placement
9. PDL BioPharma Completes Regular Quarterly Dividend Payment
10. CeNeRx BioPharma Completes $4.85 Million Financing
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... la première fois les différences entre les souches ... de celles des êtres humains . Ces ... comprendre et envisager la prise en charge efficace de ... ent diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... and HOLLISTON, Mass. , ... Inc. (Nasdaq: HART ), a biotechnology company developing ... CEO Jim McGorry will present at the ... 1, 2015 at 2:30 p.m. PT. The presentation will ... for 30 days. Management will also be available at ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
Breaking Biology Technology:
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):